New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.
A new University of Kentucky College of Medicine study published in the Journal of Biological Chemistry provides foundational information about SARS-CoV-2’s spike protein.
NEWS STORIES IN THIS ISSUE:
PREGNANT AFTER THE FIRST DOSE OF COVID-19 VACCINE — NOW WHAT?
STUDY SHOWS VACCINES MAY PROTECT AGAINST NEW COVID-19 STRAINS … AND MAYBE THE COMMON COLD
EXPANDED DASHBOARD TOOL RANKS ACCESSIBILITY OF STATE VACCINE WEBSITES
Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press’s iScience.
ORNL story tips: Modeling COVID, permafrost lost and taking the heat
As researchers try to develop therapies/vaccines to combat SARS-CoV-2, the coronavirus spike protein is a major focus since it can bind to cells. Now, researchers reporting in ACS Central Science have uncovered an active role for glycans in this process, suggesting targets for vaccines and therapies.
Researchers at ORNL are using neutron scattering at the Spallation Neutron Source to better understand how spike proteins help the COVID-19 virus infect human cells and what drugs could be effective in stopping them.
This clinical trial increased an understanding of how T cells mount a response to COVID-19 infection. These findings pave the way for diagnostic tests that detect COVID immunity based on T cells instead of antibodies. Research demonstrates that generating neutralizing antibodies rather than T cells, may not be sufficient for long-term immunity. New discoveries suggest that vaccines will need to incorporate T cell targets to generate lasting COVID-19 immunity.
A molecular biologist from the University of South Australia is working with a world leader in artificial intelligence-based drug discovery to help find a molecule that could prevent the SARS-CoV-2 coronavirus strain causing COVID-19 from infecting human cells.